Recent regulatory changes mandate faster evidence generation, creating increased complexity for the pharmaceutical industry. Systematic literature reviews (SLR) are foundational for regulatory submissions, health technology assessment (HTA) dossiers, market access support, and lifecycle strategy. Yet traditional SLR workflows still take 6–18 months, while the volume of published literature doubles every 3–5 years.
Many AI tools promised acceleration. Few deliver regulatory-grade precision, with most only automating fragments of the workflow. Few preserve governance. Fewer still are validated in production by global pharma organizations.
IMO Precision Literature Review was designed by SLR experts, and built with life science partners, to meet these needs.
Key capabilities include:
End-to-end workflow automation: From protocol refinement, search and citation management through screening, structured extraction for both abstracts and full-text articles, normalization, and reporting: all steps in the SLR process are covered and aligned to established process governance models.
Precision-first AI performance: Externally validated in peer-reviewed pharma collaborations across epidemiology, clinical outcomes, and economic burden analyses, achieving >90% accuracy in complex use cases.
Human-in-the-loop control: Automation that accelerates triage and extraction while preserving full traceability, oversight, and regulator-ready audit trails, all grounded within rigorous SLR workflows.
Clinical-grade standardization: Aligning nuanced disease definitions and outcomes across studies using IMO Health’s clinician-authored terminology backbone – strengthening precision from search through extraction.
Acceleration without losing precision
This isn’t AI bolted onto literature search. It’s clinical knowledge enhancing scalable automation to meet complex SLR needs.
In one recent global pharma cost-effectiveness review, IMO Precision Literature Review replaced a human reviewer’s workload, reduced process timelines from months to days, and captured critical data elements missed during manual review, improving both efficiency and accuracy.
Evidence generation is under immense pressure from rapidly expanding data volumes, complex trial designs, and rising regulatory expectations. We're seeing real breakthroughs where clinical precision meets scalable technology. IMO Precision Literature Review demonstrates how our clinical expertise can unlock the full value of scientific literature, delivering insights pharma can trust and defend.
As life sciences organizations face mounting pressure to scale evidence while minimizing risk, IMO Precision Literature Review sets a new standard for automation with precision, governance, and proof.
Speed is easy. Defensible evidence is hard. IMO Precision Literature Review delivers both.
